Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANIEL S BANDARI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1467482216
CMS profile
20469
Location
NEWPORT BEACH, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$458,474.31

360 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
EMD Serono, Inc. $143,966.98 80
Biogen, Inc. $96,321.37 80
TG Therapeutics, Inc. $79,442.11 56
Amgen Inc. $41,492.63 50
GENZYME CORPORATION $41,390.14 21
Vanda Pharmaceuticals Inc. $30,726.84 31
E.R. Squibb & Sons, L.L.C. $24,401.36 15
Celgene Corporation $190.15 10
Genentech USA, Inc. $185.32 7
Novartis Pharmaceuticals Corporation $155.58 5
Genentech, Inc. $150.61 3
Merz Pharmaceuticals, LLC $31.04 1
Cycle Pharmaceuticals Inc $20.18 1

Page 3 of 8; records 101–150 of 360 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANIEL S BANDARI

NPI 1467482216 · CMS profile ID 20469

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

NEWPORT BEACH, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 8; records 101–150 of 360 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1467482216?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANIEL S BANDARI, NPI 1467482216, CMS profile ID 20469. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 360 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1467482216?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). DANIEL S BANDARI, NPI 1467482216, CMS profile ID 20469. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 360 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1467482216?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
DANIEL S BANDARI, NPI 1467482216, CMS profile ID 20469, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 8; records 101–150 of 360 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1467482216?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

360 matching records · $458,474.31 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 360 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 360.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Vanda Pharmaceuticals Inc. $22.1608/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232946130 CMS
EMD Serono, Inc. $27.9908/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236894511 CMS
EMD Serono, Inc. $3.0508/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236895489 CMS
EMD Serono, Inc. $229.8407/30/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236882131 CMS
EMD Serono, Inc. $559.9607/30/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236886856 CMS
EMD Serono, Inc. $114.8407/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236887384 CMS
Biogen, Inc. $42.8807/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208302738 CMS
Biogen, Inc. $128.8007/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208313011 CMS
GENZYME CORPORATION $22.4107/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233406889 CMS
Biogen, Inc. $19.7907/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208488779 CMS
Celgene Corporation $18.5007/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184791787 CMS
Amgen Inc. $550.0007/23/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226909970 CMS
Amgen Inc. $3,300.0007/23/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226919953 CMS
Vanda Pharmaceuticals Inc. $6.6507/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232946126 CMS
Biogen, Inc. $146.3107/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208343400 CMS
EMD Serono, Inc. $45.5807/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236909083 CMS
Biogen, Inc. $14.8507/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208309779 CMS
EMD Serono, Inc. $32.2007/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236907925 CMS
Amgen Inc. $605.1507/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226923413 CMS
TG Therapeutics, Inc. $58.7607/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226254181 CMS
Amgen Inc. $124.9807/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228293396 CMS
Celgene Corporation $10.6307/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184791765 CMS
Genentech USA, Inc. $27.4207/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211505665 CMS
Vanda Pharmaceuticals Inc. $32.2007/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232946122 CMS
Amgen Inc. $12.9207/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227142828 CMS
GENZYME CORPORATION $11,967.4407/08/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1233406903 CMS
GENZYME CORPORATION $6,769.8307/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233406947 CMS
GENZYME CORPORATION $255.3007/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233406949 CMS
GENZYME CORPORATION $524.3307/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233406951 CMS
GENZYME CORPORATION $94.3807/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233406953 CMS
GENZYME CORPORATION $48.2407/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233406955 CMS
GENZYME CORPORATION $47.1907/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233406957 CMS
E.R. Squibb & Sons, L.L.C. $5,480.0007/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1184791903 CMS
Vanda Pharmaceuticals Inc. $28.4806/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232946117 CMS
Biogen, Inc. $28.2206/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208302775 CMS
TG Therapeutics, Inc. $3,712.5006/26/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226254110 CMS
TG Therapeutics, Inc. $625.5006/25/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226254114 CMS
TG Therapeutics, Inc. $346.5406/25/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226254142 CMS
TG Therapeutics, Inc. $101.0806/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226254149 CMS
TG Therapeutics, Inc. $5,737.5006/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226254194 CMS
TG Therapeutics, Inc. $722.3606/25/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226254214 CMS
Amgen Inc. $2,200.0006/24/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226893268 CMS
Amgen Inc. $3,300.0006/24/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226908986 CMS
Amgen Inc. $3,300.0006/24/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226917274 CMS
EMD Serono, Inc. $5,175.0006/24/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1236907533 CMS
EMD Serono, Inc. $34.1006/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236909797 CMS
EMD Serono, Inc. $6,555.0006/24/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1236923270 CMS
GENZYME CORPORATION $26.0806/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233406877 CMS
Celgene Corporation $4.6906/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184791743 CMS
TG Therapeutics, Inc. $22.6206/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226254103 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $479,979.37 484
PY2020 $236,409.75 231
PY2021 $335,132.12 358
PY2022 $388,278.65 402
PY2023 $311,018.33 346
PY2024 $378,375.79 296
PY2025 $458,474.31 360

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $47,025.00 5
PY2025 Principal investigator $45,707.40 19
PY2024 Principal investigator $89,165.96 29
PY2023 Recipient $8,726.00 3
PY2023 Principal investigator $121,798.60 27
PY2022 Principal investigator $105,963.60 13
PY2021 Recipient $10,000.00 1
PY2021 Principal investigator $178,564.23 11
PY2020 Principal investigator $261,137.02 30
PY2019 Recipient $25.16 1
PY2019 Principal investigator $422,986.97 53

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

24 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $303.00 12/18/2025 Non-covered Recipient Entity
MULTIPLE SCLEROSIS CENTER OF CALIFORNIA
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis No dispute reported 06/30/2026 1190313733
Recipient EMD Serono, Inc. $2,600.00 09/22/2025 Covered Recipient Physician Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117658
Principal investigator 1 F. Hoffmann-La Roche AG $3,378.00 09/22/2025 Non-covered Recipient Entity
Daniel S. Bandari, MD dba Multiple Sclerosis of Southern California
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211595478
Principal investigator 1 F. Hoffmann-La Roche AG $291.00 09/15/2025 Non-covered Recipient Entity
Daniel S. Bandari, MD dba Multiple Sclerosis of Southern California
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211595474
Principal investigator 1 F. Hoffmann-La Roche AG $291.00 09/15/2025 Non-covered Recipient Entity
Daniel S. Bandari, MD dba Multiple Sclerosis of Southern California
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211595481
Principal investigator 1 F. Hoffmann-La Roche AG $291.00 09/15/2025 Non-covered Recipient Entity
Daniel S. Bandari, MD dba Multiple Sclerosis of Southern California
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211595486
Principal investigator 1 F. Hoffmann-La Roche AG $3,378.00 09/15/2025 Non-covered Recipient Entity
Daniel S. Bandari, MD dba Multiple Sclerosis of Southern California
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211595489
Recipient EMD Serono, Inc. $2,954.00 07/31/2025 Covered Recipient Physician A Multicenter, Observational Study to Characterize the Clinical Course in a Real-World, US Cohort of Patients with Relapsing Multiple Sclerosis of Advanced Age (>50 years) Treated with Cladribine Tablets (AGING Study) No dispute reported 06/30/2026 1240117647
Principal investigator 1 F. Hoffmann-La Roche AG $8,013.00 06/20/2025 Non-covered Recipient Entity
Daniel S. Bandari, MD dba Multiple Sclerosis of Southern California
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211595470
Principal investigator 1 EMD Serono, Inc. $1,345.00 05/22/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118009
Principal investigator 1 F. Hoffmann-La Roche AG $865.00 04/25/2025 Non-covered Recipient Entity
Daniel S. Bandari, MD dba Multiple Sclerosis of Southern California
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211595462
Principal investigator 1 F. Hoffmann-La Roche AG $8,013.00 04/25/2025 Non-covered Recipient Entity
Daniel S. Bandari, MD dba Multiple Sclerosis of Southern California
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211595466
Recipient EMD Serono, Inc. $18,626.00 04/07/2025 Covered Recipient Physician A Multicenter, Observational Study to Characterize the Clinical Course in a Real-World, US Cohort of Patients with Relapsing Multiple Sclerosis of Advanced Age (>50 years) Treated with Cladribine Tablets (AGING Study) No dispute reported 06/30/2026 1240117649
Recipient EMD Serono, Inc. $17,826.00 04/07/2025 Covered Recipient Physician Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117651
Recipient EMD Serono, Inc. $5,019.00 04/07/2025 Covered Recipient Physician A Multicenter, Observational Study to Characterize the Clinical Course in a Real-World, US Cohort of Patients with Relapsing Multiple Sclerosis of Advanced Age (>50 years) Treated with Cladribine Tablets (AGING Study) No dispute reported 06/30/2026 1240117654
Principal investigator 1 EMD Serono, Inc. $1,280.00 03/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118013
Principal investigator 1 F. Hoffmann-La Roche AG $7,794.00 03/21/2025 Non-covered Recipient Entity
Daniel S. Bandari, MD dba Multiple Sclerosis of Southern California
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211595448
Principal investigator 1 F. Hoffmann-La Roche AG $865.00 03/21/2025 Non-covered Recipient Entity
Daniel S. Bandari, MD dba Multiple Sclerosis of Southern California
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211595457
Principal investigator 1 Novartis Pharmaceuticals Corporation $68.40 01/31/2025 Non-covered Recipient Entity
MULTIPLE SCLEROSIS CENTER OF CALIFORNIA
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190306255
Principal investigator 1 F. Hoffmann-La Roche AG $291.00 01/22/2025 Non-covered Recipient Entity
Daniel S. Bandari, MD dba Multiple Sclerosis of Southern California
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211595432
Principal investigator 1 F. Hoffmann-La Roche AG $865.00 01/22/2025 Non-covered Recipient Entity
Daniel S. Bandari, MD dba Multiple Sclerosis of Southern California
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211595436
Principal investigator 1 F. Hoffmann-La Roche AG $291.00 01/22/2025 Non-covered Recipient Entity
Daniel S. Bandari, MD dba Multiple Sclerosis of Southern California
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211595439
Principal investigator 1 F. Hoffmann-La Roche AG $291.00 01/22/2025 Non-covered Recipient Entity
Daniel S. Bandari, MD dba Multiple Sclerosis of Southern California
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211595444
Principal investigator 1 F. Hoffmann-La Roche AG $7,794.00 01/22/2025 Non-covered Recipient Entity
Daniel S. Bandari, MD dba Multiple Sclerosis of Southern California
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211595454